Prognostic evaluation of comorbidities in patients with myelodysplastic syndrome

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 36; no. 3; pp. 196 - 201
• Main Authors: Li, Yi, Qin, Tiejun, Xu, Zefeng, Zhang, Yue, Fang, Liwei, Zhang, Hongli, Pan, Lijuan, Hu, Naibo, Qu, Shiqiang, Li, Bing, Xiao, Zhijian
• Format: Journal Article
• Language: Chinese
• Published: China 01.03.2015
• Subjects: Abnormal Karyotype; Blood Platelets; Comorbidity; Humans; Leukocytes; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2015.03.005

To discuss the impact of comorbidities on the outcomes of patients with MDS. The clinical characteristics of 676 MDS patients with detailed comorbidities evaluations was analyzed retrospectively. There were 395/676 cases (58.4%) with comorbidities (group 1), 281/676 cases (41.6%) without (group 2). Significant differences were seen in the distribution of age (≥ 60 y), bone marrow blasts, abnormal karyotype, WHO 2008 subtypes and IPSS-R risk cohorts (P<0.05) between the two groups. While gender, HGB concentrations, WBC levels, platelet levels and serum ferritin were not significantly different (P>0.05). Independent prognostic significance of comorbidities was seen in both uni-variate and multi-variate analyses (P<0.001). According to MDS-specific comorbidity index (MDS-CI), the median survival were 32(1-153) months, 19(2-85) months and 13(1-37) months in the low-risk, intermediate-risk and high-risk cohorts respectively, while 96(1-166) months in cohorts without any comorbidities, of which significant differen